AC
GILD icon

ASB Consultores’s Gilead Sciences GILD Stock Holding History

ASB Consultores’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,373
Closed -$263K – 71
2025
Q2 		$263K Buy
+2,373
New +$253K 0.18% 104
2024
Q2 		– Sell
-4,285
Closed -$314K – 238
2024
Q1 		$314K Buy
+4,285
New +$330K 0.08% 205
2023
Q3 		– Sell
-2,992
Closed -$231K – 161
2023
Q2 		$231K Buy
2,992
+2
+0.1% +$160 0.11% 162
2023
Q1 		$248K Buy
+2,990
New +$248K 0.1% 152
2022
Q3 		– Sell
-3,257
Closed -$201K – 186
2022
Q2 		$201K Buy
+3,257
New +$202K 0.09% 171

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ASB Consultores's GILD Position: Q3 2025 in Review

ASB Consultores sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 2,373 shares — an estimated $263K sold.

ASB Consultores first reported a position in GILD in Q2 2022 and held it in 5 quarters. The position peaked at $314K in Q1 2024. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • ASB Consultores reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
  • ASB Consultores sold 2,373 Gilead Sciences shares in Q3 2025, an estimated $263K.
  • ASB Consultores first reported a position in Gilead Sciences in Q2 2022 and held it in 5 quarters.
  • ASB Consultores's Gilead Sciences position peaked at $314K in Q1 2024.
  • 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on ASB Consultores's 13F filing for Q3 2025, filed 4 Nov 2025.